Pingora Partners LLC Makes New Investment in Bristol Myers Squibb Company $BMY

Pingora Partners LLC bought a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 33,855 shares of the biopharmaceutical company’s stock, valued at approximately $1,951,000. Bristol Myers Squibb makes up approximately 1.1% of Pingora Partners LLC’s holdings, making the stock its 22nd largest holding.

Several other hedge funds have also recently bought and sold shares of the company. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb during the fourth quarter worth $25,000. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter valued at $25,000. Davis Asset Management L.P. acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter worth $27,000. Bayban acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter worth about $32,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Citigroup restated a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Guggenheim reaffirmed a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. TD Cowen initiated coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. raised their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $66.06.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $67.68 on Thursday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The stock has a market capitalization of $138.25 billion, a P/E ratio of 14.91, a P/E/G ratio of 0.18 and a beta of 0.22. The firm’s 50-day moving average is $61.25 and its two-hundred day moving average is $59.60. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.7%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.